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Fermented dairy products provide nutrients in our diet, some of which are produced by the action of microorganisms during
fermentation. These products can be populated by a diverse microbiota that impacts the organoleptic and physicochemical
characteristics foods as well as human health. Acidification is carried out by starter lactic acid bacteria (LAB) whereas other
LAB, moulds, and yeasts become dominant during ripening and contribute to the development of aroma and texture in dairy
products. Probiotics are generally part of the nonstarter microbiota, and their use has been extended in recent years. Fermented
dairy products can contain beneficial compounds, which are produced by the metabolic activity of their microbiota (vitamins,
conjugated linoleic acid, bioactive peptides, and gamma-aminobutyric acid, among others). Somemicroorganisms can also release
toxic compounds, the most notorious being biogenic amines and aflatoxins. Though generally considered safe, fermented dairy
products can be contaminated by pathogens. If proliferation occurs during manufacture or storage, they can cause sporadic cases
or outbreaks of disease.This paper provides an overview on the current state of different aspects of the research onmicroorganisms
present in dairy products in the light of their positive or negative impact on human health.
1. The Microbial World Diversity in
Fermented Dairy Products
Fermented dairy products are an important part of our diet
and can contain a diverse microbiota. Lactic acid bacteria
(LAB) are the main players during milk fermentation, con-
verting lactose to lactic acid, which results in an increased
acidity that makes growth conditions of microorganisms
other than LAB increasingly unfavourable.The LAB involved
in fermented dairy processing belong to diverse micro-
bial groups that are characterized by different nutritional,
metabolic, and culture requirements as well as different
technological properties. The most common LAB present in
milk includes species belonging to the genera Lactobacillus,
Streptococcus, Leuconostoc, Enterococcus, and Lactococcus [1].
Lactococcus lactis ssp. lactis and Lactococcus lactis ssp.
cremoris, in particular, are primarily known because of their
role as starter cultures for the cheese industry. The genus
Lactobacillus currently consists of 174 different species. Lac-
tobacilli play two main roles in fermented dairy products, as
starters or as secondary microbiota. Lactobacillus delbrueckii
ssp. bulgaricus and Lactobacillus delbrueckii ssp. lactis are
usedworldwide as starters in yoghurt production. In contrast,
other lactobacilli initially present in raw milk increase in
number during the manufacture of dairy products and can
become particularly dominant during cheese ripening [2].
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These populations, which are often referred to as nonstarter
LAB (or NSLAB), are able to carry out proteolysis and lipol-
ysis, subsequently producing many end products that con-
tribute to the development of flavour and texture of cheeses
[3]. The species more frequently involved include Lacto-
bacillus helveticus, Lactobacillus casei, Lactobacillus paracasei,
Lactobacillus plantarum/paraplantarum, Lactobacillus rham-
nosus, Lactobacillus curvatus, Lactobacillus brevis, Lactobacil-
lus sake, Lactobacillus pentosus, Lactobacillus acidophilus,
Lactobacillus reuteri, Lactobacillus johnsonii, Lactobacillus
crispatus, Lactobacillus fermentum, Lactobacillus buchneri,
and Lactobacillus gasseri. While the analysis of the pres-
ence and levels of these species in food products can be
underestimated with the use of culture-dependent methods,
the development of culture-independent techniques for the
study of microbial communities, such as PCR-DGGE, PCR-
TTGE, qPCR, 16S rRNA gene sequencing, and metagenomic
approaches, is contributing to a deeper knowledge of the
fermented dairy products microbiota. Although many strep-
tococcal genera are pathogenic, Streptococcus thermophilus
carries a “GRAS” status [4]. S. thermophilus is a thermophilic
LAB widely used as starter culture in the manufacture of
dairy products, notably in the yoghurt production, and is
considered as the second most important industrial dairy
starter after La. lactis. Enterococci are the most controversial
group of food-associated LAB and they could act either as
starter cultures, probiotics, spoilage, or pathogenic organisms
depending on the strain considered [5]. Leuconostoc, in par-
ticular the species Leuconostocmesenteroides and Leuconostoc
pseudomesenteroides, have the ability to produce CO
2
which
is responsible for the eye formation in some types of cheeses
[6]. Other microbial groups comprising Gram-positive and
Gram-negative bacteria, as well as yeasts and moulds,
also contribute to the organoleptic and physicochemical
properties of dairy products. In this regard, Gram-positive
bacteria like Corynebacterium spp., Arthrobacter spp., and
Brevibacterium are essential in smear-ripened cheeses. Propi-
onibacterium freudenreichii subsp. shermanii carries out the
propionic fermentation through the conversion of lactic acid
formed by acidifying bacteria to acetate, propionate, and
CO
2
, the latter being responsible of the eye formation in
Swiss-type and other cheeses.
Bifidobacteria represent an important group of nonstarter
microorganisms that are included in some dairy products,
mainly fermented milks, because of the health-promoting
properties attributed to some of them. Although they usually
have a considerably slower growth-rate than starter cultures,
their proliferation will contribute to increase levels of lactate
and acetate in final products.
Regarding undesirable microorganisms in dairy prod-
ucts, special attention should be focused on the spore-
former bacteria which are important contaminants in the
dairy industry.Thus, microorganisms belonging to the genus
Clostridium, such as Clostridium tyrobutyricum or Clostrid-
ium butyricum, are considered the main organisms respon-
sible for the late-blowing of cheese [7]. Pathogenic clostridia
will be commented on below.The presence of contaminating
Gram-negative bacteria, mainly enterobacteria, is rather
common in dairy foods, sometimes reaching levels up to
106-107 CFUg−1 in cheeses and they can contribute to a
worsening of sensory quality of dairy products [8].
Yeast and moulds are important microbial populations
in dairy products, especially in some types of cheeses. As
with bacteria, the development of culture independent DNA-
based analyticalmethods has allowed detection of genera and
species not previously found in dairy environments, such as
Torrubiella and Malassezia [9]. In cheese, yeasts and moulds
play a key role in the development and enhancement of tex-
ture and flavour through the activity of somemicrobial extra-
cellular enzymes in the food matrix. The yeast species most
frequently found in dairy products include Kluyveromyces
lactis,Debaryomyces hansenii, Candida spp.,Geotrichum can-
didum, and Yarrowia lipolytica. Among moulds Penicillium,
Geotrichum, Aspergillus, Mucor, and Fusarium are the most
common genera [10].
2. Beneficial and Toxic Compounds
Released by LAB, Yeasts, and Moulds
during Fermentation
Some health-promoting properties of fermented dairy prod-
ucts are due to the synthesis or to the release from the
food matrix of bioactive compounds as a result of the
metabolic activity of LAB, propionibacteria, yeast, and
moulds. Worth mentioning are among others, conjugated
linoleic acid (CLA), exopolysaccharides (EPS), bioactive
peptides, vitamins, gamma-aminobutyric acid (GABA), and
oligosaccharides [11].
Although milk contains vitamins, fermentation by LAB
often leads to the enrichment of some of them, as it is
the case for vitamin B
12
, folic acid, and biotin produced by
propionibacteria [12] or the higher synthesis of folate in milk
fermented with some LAB with respect to nonmilk complex
culture media [13]. CLA is a native component of milk fat.
Its content can be increased in fermented milk through
bioconversion of unsaturated fatty acids such as linoleic and
linolenic acids by different LAB [14, 15]. The functionality
of CLA has been well documented with respect to its anti-
inflammatory [16], antiatherogenic, and antioxidant proper-
ties [17].
Bioactive peptides are specific fragments of milk proteins
that are released by proteolytic activity from caseins pre-
dominantly and also from whey proteins. Antihypertensive,
antimicrobial, antioxidative, and immune-modulatory activi-
ties have been described for peptides released as a result of the
activity of LAB in fermented milk products [18]. In general,
their bioactive characteristics are based on the specific amino
acid sequence and chain length (generally from two to
twenty residues) as well as on their resistance to hydrolysis.
The most studied mechanism of bioactive peptides is the
antihypertensive action displayed by the inhibition of the
angiotensin-I-converting enzyme (ACE; peptidyldipeptide
hydrolase, EC 3.4.15.1) which regulates blood pressure [19].
Some Lactobacillus-fermented milks and cheeses with added
probiotic lactobacilli revealed ACE-inhibitory activity [20,
21]. GABA is another compoundwith blood pressure repress-
ing properties; it has been demonstrated to be produced in
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Table 1: Some examples of outbreaks caused by fermented dairy products and the pathogen involved.
Pathogen Fermented dairy products Outbreak details Reference
Brucella Pecorino cheese 7 cases. Made from raw milk and insufficiently aged. [105]
Clostridium botulinum Yoghurt 27 cases, 1 death. Insufficient processing of hazelnut conserveused as a flavour. [106]
Listeria monocytogenes Hard cheese 12 cases, 4 deaths. Postmanufacture contamination. [107]
Salmonella Hard cheese Estimated 3000 cases. Cheese made from raw milk. [108]
Staphylococcus aureus Sheep milk cheese 25–27 cases. Raw milk used in production. [109]
STECO157:H7 Gouda cheese
41 cases. Raw milk used to make cheese and numerous
production/handling problems including insufficient ageing. [110]
Yoghurt 16 cases, 13 hospital admissions, 5 haemolytic uraemicsyndrome. Possible improperly cleaned pump. [111]
There are numerous other reports in the literature but many of them do not provide details on the dairy product involved. The table above includes data only
for dairy products made with a starter culture. A more comprehensive list of outbreaks involving any kind of cheese is given elsewhere [112].
fermented milk by Lb. casei Shirota and La. lactis through
transformation of glutamic acid derived from milk proteins
[22]. Bacteriocins are also among the beneficial peptides
intrinsically synthesized by some LAB duringmilk fermenta-
tion and their usefulness in preventing growth of undesirable
and pathogenic microorganisms during milk fermentation
has been commented on above.
Galactooligosaccharide (GOS) synthesis by LAB is due
to a transgalactosylation side-line activity by 𝛽-galactosidase
on lactose, the main sugar of milk. GOS have recognized
prebiotic effect on intestinal microbiota, promoting selective
growth of bifidobacteria [23, 24]. EPS are complex extracel-
lular carbohydrate polymers produced by some microorgan-
isms. They can protect the producer strains against environ-
mental adverse factors and some of them positively interact
with the colonic microbiota and with the immune system of
the host [25, 26].
Special mention is deserved of bioactive peptide compo-
nents of proteins secreted by LAB and probiotic bacteria.This
is the case of the enriched serine/threonine peptide derived
from one of the main extracellular proteins produced by Lb.
plantarum, which displayed immunomodulatory properties
after being released during digestion [27].
Although the metabolic activity of microorganisms dur-
ing dairy fermentation yields mostly beneficial compounds,
in some cases metabolic activities result in the release of toxic
substances for the consumer. Two types of toxic compounds
have been identified in dairy products, mycotoxins produced
by some fungi, and biogenic amines (BA) mainly due to the
metabolic activity of some LAB.
Mycotoxins are chemical hazards synthesized primarily
by three genera of filamentous fungi: Aspergillus, Fusarium,
and Penicillium [28]. They are termed secondary metabo-
lites, because they are not essential for normal growth
and development. Although fungi can collectively produce
hundreds of mycotoxins, only trichothecenes, fumonisins,
and zearalenone (produced by Fusarium species) and afla-
toxins, ochratoxins, and patulin (produced byAspergillus and
Penicillium species) are of note from a health point of view
[28]. These secondary metabolites are products of multistep
biochemical pathways. The genes encoding the synthase, the
modifying enzymes, the transporters, and the transcriptional
regulators are typically located next to one another in a
gene cluster [29]. In milk and dairy products mycotoxins
mainly come from feed contaminated either in the field or
during drying and storage. One of the most economically
importantmycotoxins worldwide is aflatoxin.This polyketide
produced mainly by Aspergillus flavus and Aspergillus para-
siticus is a potent carcinogen [28]. Aflatoxin M1, that results
from the metabolic conversion of aflatoxin B1, can occur
in milk and milk products from animals consuming feed-
stuffs contaminated with B1 aflatoxins. Aflatoxin-producing
Aspergillus can contaminate grain before harvest or during
storage; favourable conditions of temperature, humidity, and
mechanical kernel damage during harvesting, among other
factors, may favour the active production of aflatoxin B1 in
contaminated grains. Aflatoxin B1 is transformed to aflatoxin
M1 in the liver of lactating animals and is excreted by the
mammary gland. The potential occurrence of mycotoxins in
dairy products and mainly in milk makes them a particular
risk for humans because of their negative effects for adults
and, especially, children [30].
The other toxic compounds mainly associated to the
metabolismof some bacteria are BA.These are low-molecular
weight nitrogenous organic bases with biological activity,
mainly synthesized by decarboxylation of the corresponding
amino acids. The most important and frequent BA found
in dairy products are histamine, tyramine, and putrescine,
which are produced by decarboxylation of histidine, tyrosine,
and ornithine, respectively. Putrescine can also be synthe-
sized by deimination of agmatine. Cadaverine (originating
from lysine decarboxylation) is found less frequently in
dairy products [31]. BA are naturally present in vegetables,
animals, and humans, being involved in important biological
processes. Many bacteria of different genera and species have
the capacity to produce BA. Gram-negative bacteria (mainly
Enterobacteriaceae) that can be present in milk are able
to produce histamine, putrescine, and cadaverine [32–34].
However, themainBAproducers in dairy products aremostly
LAB of the genera Enterococcus, Lactobacillus, Leuconostoc,
Lactococcus, and Streptococcus [35–39]. These bacteria can
be (i) present in milk, (ii) introduced by contamination
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Table 2: Beneficial and detrimental microbial compounds that can be released in fermented dairy products during fermentation and the
main producer microorganisms.
Compounds Main producer microorganisms in dairy products Reference
Beneficial [11, 12, 15, 77]
Conjugated linoleic acid (CLA) BAL (Lactobacillus, Lactococcus, and Bifidobacterium)
Microbial exopolysaccharides (EPS) BAL (Lactobacillus, Lactococcus, Pediococcus, Streptococcus thermophilus, andBifidobacterium)
Oligosaccharides BAL (Bifidobacterium and Lactobacillus) and Kluyveromyces lactis
Vitamins (B12, biotin, and folic acid)
BAL (Lb. plantarum, Bifidobacterium, S. thermophilus, Lb. delbrueckii, and
Propionibacterium)
Gamma-aminobutyric acid (GABA) BAL (Lactococcus, Enterococcus, Lactobacillus, Pediococcus, Streptococcus, andLeuconostoc)
Bioactive peptides:
Immune modulatory Lactobacillus GG
Antihypertensive Lactobacillus GG, Lb. helveticus, and S. thermophilus,
Antimicrobial Lb. helveticus and Lb. acidophilus
Antioxidative Bifidobacterium longum and Lb. delbrueckii
Bacteriocins BAL (Lactococcus, Enterococcus, Lactobacillus, Pediococcus, Streptococcus,Bifidobacterium, and Leuconostoc) [101]
Detrimental
Mycotoxins: [28]
Aflatoxins, ochratoxin, and patulin Aspergillus and Penicillium
Trichothecenes, fumonisins, and
zearalenone Fusarium
Biogenic Amines: [31, 38]
Tyramine BAL (Enterococcus, Lb. curvatus, and Lb. brevis)
Putrescine BAL (Enterococcus, Lb. curvatus, Lb. brevis, and La. lactis) andEnterobacteriaceae
Cadaverine Enterobacteriaceae
Histamine BAL (Lb. buchner and, S. thermophilus)
throughout the entire process of cheese production, (iii) and
even part of starter or adjunct cultures [40]. Among the
fermented dairy products, cheeses can have the highest BA
concentrations, because of their complex microbiota and the
availability of precursor amino acids from casein proteolysis.
In fact, BA concentrations up to 2,000mg per kg of cheese
have been reported [41, 42].The intake of such contaminated
foods could cause serious health problems. For this reason,
during the recent past the metabolic pathways involved in
the synthesis of these compounds and the environmental
conditions favouring their accumulation in foods have been
studied in depth [40], in parallel with the development of
reliable detection methods either for BA or for the microbial
BA producers [43, 44].
A general picture of beneficial and detrimental com-
pounds produced by microorganisms present in dairy prod-
ucts is indicated in Table 2.
3. Probiotics and Mechanisms of
Beneficial Action
Probiotics are live microorganisms which confer a health
benefit on the host when administered in adequate amounts
[45]. The most commonly investigated and commercially
available probiotics are mainly microorganisms from species
of the genera Lactobacillus and Bifidobacterium. In addi-
tion, several others such as Propionibacterium, Streptococcus,
Bacillus, Enterococcus, Escherichia coli, and yeasts are also
used [46, 47]. Probiotics must be able to survive in the
gastrointestinal tract and be resistant to gastric juices and
bile. They should exert benefits to the host through their
activity in the human body. In order to confer health benefits,
they should be nonpathogenic and nontoxic and provide
protection against pathogenic microorganisms by means of
multiple mechanisms [45]. In addition, probiotics should
be lacking transferable antibiotic resistance genes. Different
bacterial strains of the same genus and species may exert
different effects on the host. The most promising health
effects of probiotics in human intervention studies include
amelioration of acute diarrhoea in children, reduction of the
risk of respiratory tract infections, relief of children’s milk
allergy/atopic dermatitis, and alleviation of irritable bowel
syndrome. Probiotics may exert their beneficial health effects
by normalization of the host’s microbiota, by inhibition of
pathogens, by interaction with the immune system of the
host, and through their own metabolic activity. Probiotics
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may also enhance the resilience of microbiota against detri-
mental outside factors. However, the molecular mechanisms
behind the effects are largely unknown.
3.1. Inhibition of Pathogens. Clinical and animal studies
have demonstrated that specific probiotics are effective in
alleviating infections, but the mechanisms of action are not
completely understood. Additionally, beneficial properties
and efficacy can vary considerably among different strains
from the same species. Possible mechanisms of probiotic
action include (1) hindering the adsorption, (2) cell inter-
nalization of the pathogen, (3) production of metabolites
and substances with a direct effect on the pathogen, and (4)
crosstalk (immunomodulation) with the cells in establishing
the protection [47, 48]. The possible mechanisms by which
probiotics may act against infections are presented in Table 3.
The gastrointestinal and respiratory tracts are covered
by mucosal epithelial surfaces which are constantly exposed
to numerous microorganisms and serve as primary ports
of entry for most infectious viruses. Pathogen attachment
to a host cell is the first step in the disease process, and,
therefore, interruption of this attachment could be beneficial
to the host. Probiotic bacteria may bind directly to the
pathogen and inhibit pathogen attachment to the host cell
receptor. For instance, there is evidence that, in vitro, specific
strains of lactobacilli and bifidobacteria are able to bind and
inactivate rotavirus [49] and vesicular stomatitis virus [50].
In addition, adhesion of probiotics on the epithelial surface
[51–53] may block pathogen attachment by steric hindrance,
cover receptor sites in a nonspecific manner, or inhibit
binding of pathogens to specific carbohydrate receptors.
Luminal secretions (mucus, glycolipids, and protective pep-
tides) and antimicrobial peptides (defensins)may also protect
epithelial cells from infections. Intestinal mucins may bind to
pathogens through specific mucin-bacterial/viral interaction
and inhibit their adherence to the epithelial cells [54].
Probiotics may induce mucosal regeneration by increasing
mitosis rate in the small intestine and increasing the numbers
of cells in the villi [55, 56]. They can also promote intestinal
epithelial homeostasis via soluble proteins [57]. Probiotics
also show direct activity against pathogens by producing
antimicrobial substances such as organic acids, hydrogen
peroxide, diacetyl, short chain fatty acids, biosurfactants, and
bacteriocins. It is widely known that intestinal permeability
increases in gastrointestinal infections, as pathogens attach
to cell receptors below the tight junctions on the basolateral
membrane, thusmodifying tight junctions and disturbing the
barrier. A possible mechanism of probiotics beneficial action
is the reinforcement of gut defence barrier by normalizing
permeability and disturbed gutmicrobial ecology [47, 58, 59].
3.2. Interaction with the Immune System. An optimally func-
tioning immune system is important for the maintenance
of physiological integrity and health. The immune system
provides defence against infections caused by pathogenic
microorganisms. It also modulates our health and well-being
in many ways sometimes by up- or downregulating the
defence system. An effectively functioning immune system
is fundamental for protection against infectious diseases.
One possible probiotic mechanism against infections could
be the stimulation of the gut immune system. In the
gut epithelial cells, probiotics can be recognized by toll-
like receptors [60–63]. Probiotics may, therefore, modulate
cytokine expression patterns through epithelial cells [64]
and/or through macrophages and dendritic cells [65–70].
Many experimental studies in vitro show that certain strains
of probiotics are capable of providing protection against
infections by stimulating antiviral, cytokine, and chemokine
responses in gastrointestinal and respiratory epithelial cells
or immune cells. Administration of lactobacilli to mice
may affect respiratory infections by reducing virus titre in
the lungs and increasing survival rate of the animals via
stimulating innate immune responses [47, 71].
4. Strategies to Improve Viability
and Functionality of Probiotics in
Fermented Dairy Products and the
Gastrointestinal Tract
Probiotics are generally added as adjunct cultures in fer-
mented dairy products.Their viability in foods should ensure
the minimum daily dose able to provide the health benefits
attributed to the specific functional food product in which
they are included. However, probiotics often show poor
survival in the food matrix, due to factors such as low
pH, oxygen content, temperature, and the presence of other
microorganisms. In addition, probiotics should remain viable
at sufficient levels through the gastrointestinal transit in order
to arrive alive to the site of action, the intestine. During
digestion, they have to face different harsh physiological
barriers, including digestive enzymes, the acidic pH of the
stomach, and bile salts in the intestine and then compete
with members of the resident intestinal microbiota for scarce
fermentable substrates. In addition, not only the viability
but also the maintenance of the metabolic activity and the
beneficial properties of strains are important [46].
Some strategies targeting the food product and/or the
composition of starter cultures have been used to improve
viability of microorganisms in fermented dairy products.
The selection and combination of appropriate LAB strains
[72, 73], the control of the final pH and postacidification phe-
nomenon by different approaches [74, 75], or the addition of
protectors and oxygen scavengers [6, 76] are some examples.
Other strategies affecting the microorganism itself are
useful to increase survival in the food matrix and during the
gastrointestinal transit. For example, the selection of EPS-
producing probiotics could be an appropriate way to obtain
strains with adequate viability, since these polymers can act
as protectors of the producing bacteria, contributing to their
viability [77, 78]. Resistant derivatives to technological or
physiological conditions are easy to obtain by exposing the
probiotic to sublethal stressing factors (freezing, heat, drying,
oxygen, acid, bile, NaCl, etc.). Usually, the resistant microor-
ganisms present a stable phenotype with higher viability,
but they often develop cross-resistances to other stresses
[79]. Adaptation to stress may also influence physiological
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Table 3: Summary of the possible mechanisms by which probiotics exert healthy effects.
Mechanisms
(1) By inhibiting the adhesion of pathogens to the epithelium in a nonspecific manner or by competing for specific receptors and nutrients
(2) By producing antimicrobial agents against pathogens
(3) By inducing mucin production in the epithelial cells
(4) By strengthening the mucosal barrier through the regeneration of epithelial cells and reduction of permeability
(5) By modulating the immune system through the antigen-presenting cells
(6) By inducing cytokine production from the epithelial and immune cells, resulting in enhanced cell-mediated immune responses and
the activation of cytotoxic T cells, phagocytic cells, and NK cells
(7) By increasing the proliferation of B cells through the induction of cytokines, which travel to secondary lymphatic organs in
mucosa-associated lymphoid tissue and differentiate into immunoglobulin-producing plasma cells that may return to gut-associated
lymphoid tissue by inducing the production of specific antibodies such as secretory IgA
characteristics of microorganisms that could hence impact
technological and sensory aspects as well as probiotic-related
properties [80–82]. Gene modification is another way to
increase stress tolerance. However, the use of such genetically
modified microorganisms is limited by current regulation in
several countries [83, 84].
Addition of some food ingredients to food could enhance
survival of probiotics, as is the case of prebiotics. These can
be defined as “a selectively fermented ingredient that results
in specific changes in the composition and/or activity of the
gastrointestinal microbiota, thus conferring benefits upon
host health” [85]. Most prebiotics are complex carbohydrates
from plant origin. Probiotics have been employed in combi-
nation with prebiotics (synbiotics) to improve their viability;
prebiotics often act as entrapping matrices during the gas-
trointestinal transit, further releasing the microorganism in
the intestine and then serving as fermentable substrates [86].
Microencapsulation of probiotics on different materials has
been also used to enhance the viability [87].
5. Opportunistic and Pathogenic
Microorganisms and Mechanisms of
Detrimental Action in the Host
Gram-positive bacteria associated with food poisoning
comprise mainly nonsporulating microorganisms from the
genera Staphylococcus and Listeria, as well as sporulating
Clostridium tertium, Clostridium perfringens, Clostridium
botulinum, and members of the Bacillus cereus group [88].
Some Gram-negative bacteria contaminating dairy foods are
considered as indicators of poor hygiene and may constitute
a health risk if pathogenic species are present. These include
the species E. coli, Pseudomonas aeruginosa, Klebsiella pneu-
moniae, and Citrobacter freundii and the genera Enterobacter,
Proteus, Psychrobacter,Halomonas, and Serratia [89]. Specific
pathogens aremainly particular enterotoxigenicE. colipatho-
types and Salmonella.
The proportion of foodborne disease outbreaks and
sporadic cases that can be attributed to the consumption of
dairy products was approximately 4–7% of outbreaks in the
USA from 1998 to 2008 [90] and in 2009-2010 this figure was
13% [91]. Only a proportion of these would be attributable to
fermented dairy products. In the EU, cheese was identified as
the vehicle of transmission in 41 of 763 (5.4%) outbreaks and
other dairy products (excluding milk) and in only 4 (0.5%)
during 2012 [92]. Inspection of the data shows that many
of these outbreaks are, in fact, associated with coagulated
dairy products that have not been fermented but produced by
direct acidification.The behaviour of pathogens is different in
cheeses producedwith or without a starter culture [93]. Of six
dairy-associated outbreaks of listeriosis recorded in the USA
from 1998 to 2008, four were caused by Mexican-style queso
fresco/queso blanco which are soft cheeses produced without
starter cultures [94].
Raw (unpasteurized) milk can contain a variety of bac-
terial pathogens which may cause disease if not eliminated
during production [95]. Disease can be caused by two
major mechanisms: infection by the organism or ingestion
of preformed toxin. Listeria monocytogenes [96], E. coli
O157:H7, and other shiga toxigenic E. coli (STEC) [97]
can cause significant clinical outcomes. Around 20–30% of
listeriosis cases are fatal while STEC infections can cause
kidney failure and, more rarely, death, especially in young
people. Salmonellosis is usually a diarrhoeal disease, while
brucellosis is a systemic infection causing symptoms such as
fever, fatigue, and myalgia. In contrast, both Staphylococcus
aureus and C. botulinum can grow in foods to form toxins
[98, 99]. Staphylococcal enterotoxin can result in emesis
when ingested, while botulinum toxin can result in paralysis
and death in an estimated 17.3% of domestically acquired
foodborne cases of botulism in United States [100].
In cheesemaking using raw milk, initial production
steps can involve periods where the milk is held at >30∘C,
temperatures which may allow contaminating bacteria to
proliferate. However, in general, subsequent steps result in
inactivation of bacterial pathogens. The use of a starter
culture is critical because of the resulting lowpHconcomitant
with the production of lactic acid [101]. During fermentation,
milk and curdmay rapidly reach a pHatwhich pathogenswill
not grow and subsequently their levels will decline as long as
the pH remains low. The potential for pathogens to survive
manufacture and ripening to contaminate the retail product
made from rawmilk dependsmainly on (1) the initial levels of
the pathogen, (2) growth and entrapment in the curd during
manufacture, (3) the rate of microbial population decrease
during ripening, (4) antagonistic activity of LAB present in
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milk or added as starters, (5) physicochemical parameters,
such as pH, salt content, and water activity, and (6) the length
of ripening.
In cheeses which are mould-ripened or bacteria smear-
ripened (e.g., smear cheeses), the fungi or bacteria used to
achieve the particular characteristics of the product cause a
rise in the pH during ripening and so potentially allowing
surviving pathogens to grow. The fate of various pathogens
in cheese production has been reviewed [102].
Pasteurisation is the common method to eliminate
pathogens from milk prior to the manufacture of dairy
products, and so when contamination occurs it is a result of
poor hygiene practices postpasteurisation or pasteurisation
failure. While there has been much public debate about the
relative merits of consuming dairy products made with raw
milk versus pasteurised milk, when consumption volumes
are considered, rawmilk products cause a disproportionately
large proportion of cases of foodborne disease compared to
those made with pasteurised milk [91, 103, 104].
As a whole, despite the overall excellent safety record of
fermented dairy products, outbreaks and incidents of disease
still can result from their consumption [105–112]. Table 1 gives
some examples of outbreaks, the pathogens that caused them,
and the reasons why they occurred.
6. Strategies for Counteracting Pathogens
and Harmful Microorganisms in Fermented
Dairy Products
The most common approach to guarantee the safety of
fermented dairy products is to ensure that the milk used in
theirmanufacture is pathogen-free (or contains an acceptably
low level of some pathogens like S. aureus) followed by the
prevention of recontamination during production, distribu-
tion, and retail sale. With current technology, pathogen-free
raw milk is difficult to produce, but using food quality milk
froma source that submits animals to a strict pathogen testing
regime and has good hygiene practices in place may help to
meet this goal.
Pasteurisation (usually, the exposure to 72∘C for 15 sec-
onds, or 63∘C for 30min) is considered to be sufficient to
remove bacterial pathogens from milk intended for the use
in fermented dairy products. An alternative to pasteurisation
of milk, which is implemented in several countries, is to age
cheeses made from raw milk for 60 days as a minimum.
However, this has been shown to be ineffective under some
circumstances such as when pathogenic strains are resistant
to low pH or in postprocessing contamination of surface-
mold-ripened cheeses in which a rise of pH occurs during
maturation [113, 114].
Alternatives to pasteurisation have been sought in order
to produce safemilk for processing yet not producing the per-
ceived organoleptic changes resulting from pasteurisation.
Some examples of this are ultrahigh pressure treatment [115],
pulsed electric field (PEF) technology, and ultrasonication
[116]. High hydrostatic pressure has been applied to both
milk used to make cheese [117] and cheese itself [118] where
significant reductions in S. aureus were recorded. PEF is not
particularly effective with bacterial spores but kills vegetative
cells, typically by 4-5 log
10
CFU/mL, through the production
of pores in bacterial membranes. There may also be an
improved curd quality in cheese made using PEF milk.
Ultrasonication works primarily by cavitation which causes
shear stress and physical damage to cells, but the effects are
only significant at temperatures above 50∘C. It can be used in
combination with other physicochemical treatments [115].
There are also a number of nonphysicochemicalmeasures
which could broadly be termed biocontrol, including the
use of bacteriophages, bacteriocins/protective cultures, and
naturally-occurring chemicals, such as essential oils. Bac-
teriophages (phages) are bacterial viruses. They have been
shown to control Salmonella in cheddar cheese production
[119], S. aureus in fresh and hard cheese production [120],
and E. coli O157 in fermented milk production [121]. After
90 days of storage levels of Salmonella were consistently 2-3
log
10
CFUg−1 higher in untreated cheeses compared to those
in phage-treated cheeses. Control of L. monocytogenes by
phages has been similarly reported for smear-ripened soft
cheeses [122]. The cheese was ripened at 14∘C for 16 days,
packaged, and then stored for five more days at 6∘C. The
levels of L.monocytogenes reached 105 CFU cm−2 in untreated
cheeses at 16 days and >107 CFU cm−2 by day 21. Application
of the phage preparation eliminated L. monocytogenes and no
further growth occurred during storage. Similar results have
been reported elsewhere [123]. Starter and nonstarter LAB
can act as a protective culture [124], inhibiting the growth of
pathogens through competition (pH reduction, production
of hydrogen peroxide, etc.) and/or by the production of
bacteriocins [101]. Bacteriocins are a heterogeneous group
of antimicrobial peptides that inhibit the growth of other
bacteria. These compounds generally display action on a
narrow range of organisms. Whereas some of them only
act against other LAB, others are also able to inhibit the
growth of some foodborne pathogenic bacteria [125], serving
as natural biopreserving agents in fermented dairy products.
Nisin, a commercially available bacteriocin, has found use
in the prevention of the outgrowth of spores, particularly
those of Clostridium species [101, 125], allowing flexibility in
the formulation of dairy products such as processed cheese.
NSLAB producing bacteriocins can be used singly and in
combination with high pressure to kill pathogens in cheese
[126].
A novel idea is to use plant-derived essential oils to
control pathogens. For example, oregano and thyme essential
oils have been shown to increase the rate of inactivation of L.
monocytogenes and E. coli O157:H7 in Feta cheese [127], the
cheeses being accepted by taste panellists.
7. Concluding Remarks and Future Trends
Although the manufacture of fermented dairy products by
humanity began in prehistory, we continue innovating pro-
duction even today. Figure 1 presents a schematic overview
of the main areas of scientific and technological interest in
relation with microorganisms present in fermented dairy
products and human health.
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Figure 1: Overview of the main scientific and technological areas of interest relating microorganisms present in fermented dairy products
and human health. LAB: lactic acid bacteria; CLA: conjugated linoleic acid; GABA: gamma-aminobutyric acid; EPS: exopolysaccharides.
The extraordinary recent development of next generation
sequencing (NGS), functional genomics (with their related
dynamic techniques such as metabolomics, proteomics, and
transcriptomics), and systems biology will facilitate in the
coming years a better understanding of microbial population
dynamics occurring in fermented dairy products, as well
as a more accurate prediction of the biochemical processes
occurring in fermented milk products as depending on the
microbiota which is present. Cell biology techniques are
necessary tools for deciphering the interaction mechanisms
between pathogens and probiotics with the host, with respect
to their detrimental or beneficial action. In the case of
probiotics, this knowledgewill help in the selection of the best
strains targeting specific human populations with defined
needs. While mechanistic research advances, it is necessary
to continue and improve surveillance programs of diseases
caused by fermented dairy products; vigilance must remain
in maintaining the hygienic conditions of dairy processing.
Finally, research in new technologies providing safe alterna-
tives to milk thermal processes, such as pasteurisation, may
allow the development of safer products with organoleptic
properties more to the liking of some consumers. In spite
of the scientific advances, our knowledge on the effects of
fermented dairy products and the accompanying microor-
ganisms on human health remains incompletely understood.
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